pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,756 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT834Endpoints640BioPharma Dive243onclive165BioSpace98Fierce Biotech96raps39globenewswire health28fda recalls
therapy area
allOncology5005Rare Disease851Cardiology802Hematology772Immunology733Psychiatry & CNS582Pulmonology
  • [Podcast] Closing the Distance in Cancer Care
    This podcast episode explores the critical role community oncology plays in the U.S. healthcare system and why supporting its growth and autonomy matters for patients and providers.
    BioPharma Dive · 2mo ago↗ source
  • Merck KGaA's clients are stockpiling due to Iran war, supporting guidance boost
    Merck KGaA appears to have a big-picture view of how the Iran war is affecting the pharma industry so far. The German company is seeing an uptick in demand for its lab equipment products as ...
    Endpoints · 2mo ago↗ source
  • STAT+: Drug meant to make gene therapy safer may also make it less effective
    Encoded Therapeutics gives a heads-up to other gene therapy company about the trade-offs with a drug meant to improve safety.
    STAT
← prev
page 54 of 71
next →
23
fda press21
fda medwatch18
571
Vaccines517
Endocrinology & Metabolism293
Ophthalmology258
Infectious Disease253
Nephrology239
· 2mo ago
↗ source
  • STAT+: Scientists link boy’s tumor to gene therapy viruses, in rare finding
    Doctors have linked a boy's tumor to a gene therapy, but say the rare risks need to be weighed against the profound benefits such medicines can offer.
    STAT · 2mo ago↗ source
  • STAT+: A new kind of liver crisis is emerging in the U.S. The American diet is to blame
    Young people and women are particularly vulnerable to MetALD, a dangerous merging of metabolic disease and alcohol use.
    STAT · 2mo ago↗ source
  • STAT+: Bill Cassidy risked his legacy. It may not be enough to save his career
    Sen. Bill Cassidy risked his legacy. It may not be enough to save his career.
    STAT · 2mo ago↗ source
  • Opinion: Access to air conditioning is critical preventive care. But federal policy treats it as optional
    Access to air conditioning is critical preventive care. But federal policy treats it as optional, write Charles E. Leonard and Anthony Nicome.
    STAT · 2mo ago↗ source
  • Opinion: What can ‘blue zones’ really teach us about aging?
    Have you heard about blue zones where people tend to live much longer? They’re more complicated than they might sound.
    STAT · 2mo ago↗ source
  • Opinion: RFK Jr.’s antidepressant deprescribing push gets one thing right — and others dangerously wrong
    “Deprescribing requires gradual tapering, psychological support, careful risk stratification, and accessible alternatives — none of which Kennedy’s initiative provides at scale.”
    STAT · 2mo ago↗ source
  • Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options
    Reducing the dose of Eli Lilly’s obesity shot Zepbound could provide a safe, effective and potentially cheaper option for the maintenance of weight loss, according to new data. The findings come fr…
    Endpoints · 2mo ago↗ source
  • STAT+: Why Marty Makary was the worst FDA commissioner in 25 years
    Marty Makary, who resigned under pressure from the FDA, brought to the job a fundamental lack of understanding of the nature of the role, STAT's Matthew Herper writes.
    STAT · 2mo ago↗ source
  • Males who discuss suicide seek help less often than females, report finds
    Out of 1.5 million messages received in 2025, the Crisis Text Line found that less then 20% of the texters identified as male only
    STAT · 2mo ago↗ source
  • FDA chief Marty Makary resigns from agency, ending tumultuous tenure
    Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with drugmakers.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: European Union inks a draft deal to boost local production of medicines and avoid shortages
    The E.U. reached a provisional deal to strengthen the supply of essential medicines and avoid shortages by ‌boosting domestic production and reducing reliance on imports.
    STAT · 2mo ago↗ source
  • EU reaches provisional deal on Critical Medicines Act
    The Critical Medicines Act reached its next milestone on Tuesday, after the European Parliament and the Council provisionally voted it through. The proposed regulation aims to improve the European…
    Endpoints · 2mo ago↗ source
  • STAT+: Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in
    Food and Drug Administration Commissioner Marty Makary is resigning from his role after a tumultuous tenure.
    STAT · 2mo ago↗ source
  • FDA Commissioner Makary resigns
    FDA Commissioner Marty Makary has resigned after his job status hung in the balance for days. President Donald Trump confirmed the news Tuesday in a social media post. Makary’s decision centered ...
    Endpoints · 2mo ago↗ source
  • Iran war disruptions begin to emerge upstream of the pharma supply chain
    As the Iran war enters its third month, its knock-on effects on raw materials, energy costs and shipping are beginning to be felt in the pharma industry. While the Middle East is barely a player ...
    Endpoints · 2mo ago↗ source
  • What I learned at a journalism fellowship about covering healthcare AI
    Last week, I was reminded that reporting on AI in healthcare requires continuous scrutiny of the incentives that drive it. Thanks to a fellowship hosted by SABEW, in partnership with ...
    Endpoints · 2mo ago↗ source
  • Supreme Court extends mifepristone deadline
    The deadliest drug in the country, the new name for PCOS, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’
    In this edition of STAT Health Tech: Hims earnings, Omada's PBM strategy, and the uphill battle faced by new sepsis algorithms.
    STAT · 2mo ago↗ source
  • STAT+: Hims’ sales miss as telehealth competition grows
    Bristol's partnership with Hengrui Pharma, Viiv loses HIV treatment case, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
    A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.
    BioPharma Dive · 2mo ago↗ source
  • Five burning Qs for Isomorphic Labs after $2.1B raise for AI biotech
    Isomorphic Labs said Tuesday it had closed a $2.1 billion Series B round, cementing its bellwether role in using AI for drug discovery. For privately held companies, Isomorphic’s raise is the secon…
    Endpoints · 2mo ago↗ source
  • Pfizer and Arvinas give disappointing breast cancer drug to Rigel
    Pfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals. T…
    Endpoints · 2mo ago↗ source